Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Simulations PlusSLP 85 EV-to-EBIT is 27.75 as of Jul. 14, 2026, which is 53% below its 10-year median of 58.67. GuruFocus rates SLP with a GF Score™ of 85/100 and a GF Value™ of $35.40 (Significantly Undervalued). The stock has 7 warning signs investors should review. Among 468 Healthcare Providers & Services companies, Simulations Plus ranks worse than 73.08% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Simulations Plus's Enterprise Value for the quarter that ended in May. 2026 was $295.89 Mil.
Simulations Plus's EBIT for the trailing twelve months (TTM) ended in May. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $11.50 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Simulations Plus EV-to-EBIT Related Terms
Simulations Plus EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Simulations Plus's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, Simulations Plus's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Simulations Plus EV-to-EBIT vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Simulations Plus's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Simulations Plus's EV-to-EBIT falls into.
Simulations Plus's current Enterprise Value is $319.20 Mil.
Simulations Plus's EBIT for the trailing twelve months (TTM) ended in May. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $11.50 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Simulations Plus (SLP) has a EV-to-EBIT of 27.75 as of Jul. 14, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Simulations Plus and its competitors. This is 53% below median its historical median of 58.67. Over the past decade, Simulations Plus' EV-to-EBIT has ranged from 18.85 to 196.03. According to the industry distribution chart, Simulations Plus ranks #342 out of 468 companies in the Healthcare Providers & Services industry, placing it in the top 73.1%.
Is Simulations Plus' EV-to-EBIT too high?
Simulations Plus' current EV-to-EBIT of 27.75 is 53% below median its 10-year median of 58.67. Over the past 10 years, this metric has ranged from a low of 18.85 to a high of 196.03. The Healthcare Providers & Services industry median EV-to-EBIT is 15.87. Simulations Plus' value of 27.75 is 74.9% above this industry median. Based on the distribution chart, Simulations Plus ranks #342 out of 468 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Simulations Plus has a GF Score™ of 85/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Simulations Plus' EV-to-EBIT compare to TBRG and CARL?
According to the Healthcare Providers & Services industry distribution chart, Simulations Plus ranks #342 out of 468 companies for EV-to-EBIT. This places Simulations Plus in the lower half of its industry. The industry median EV-to-EBIT is 15.87. Simulations Plus' value of 27.75 is 74.9% above this benchmark. Historically, Simulations Plus' own EV-to-EBIT has ranged from 18.85 to 196.03 over the past decade. While the company's 10-year median is 58.67 vs. the industry median of 15.87, Simulations Plus has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Healthcare Providers & Services company?
The median EV-to-EBIT among Healthcare Providers & Services companies is 15.87, based on 468 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Simulations Plus's current EV-to-EBIT of 27.75 is 74.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Simulations Plus and its competitors. For the Healthcare Providers & Services industry, the median EV-to-EBIT is 15.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Simulations Plus's current EV-to-EBIT is 27.75, which is 53% below median its own 10-year median of 58.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Simulations Plus stock overvalued right now?
Based on GuruFocus' analysis, Simulations Plus (SLP) is currently considered Significantly Undervalued. The stock's GF Value™ is $35.40, compared to a current price of $18.23 — trading 48.5% below its estimated fair value. The current EV-to-EBIT is 27.75, which is 53% below median its 10-year median of 58.67 and 74.9% above the Healthcare Providers & Services industry median of 15.87. Simulations Plus' overall GF Score™ is 85/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Simulations Plus (SLP), the current EV-to-EBIT is 27.75 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Simulations Plus (SLP) Overvalued in 2026?
Based on GuruFocus' analysis, Simulations Plus stock appears to be undervalued.
The current stock price of $18.23 is trading 48.5% below its estimated GF Value™ of $35.40.
GuruFocus considers Simulations Plus to be Significantly Undervalued.
Key valuation signals for SLP:
EV-to-EBIT: 27.75 (53% below median its 10-year median of 58.67)
GF Value™: $35.40 vs. price of $18.23 (48.5% below fair value)
Industry Position: 74.9% above the Healthcare Providers & Services median (#342 of 468)
No single metric tells the full story. See the SLP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Simulations Plus Inc is engaged in the software industry. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.
85GF Score
Get the complete analysis for SLP
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SLP has been successfully added to your 
